Joyce O’Shaughnessy
Baylor University(US)Sarah Cannon Research Institute(GB)Texas Oncology(US)Baylor University Medical Center(US)Sarah Cannon(US)The US Oncology Network(US)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Cancer Genomics and Diagnostics
Most-Cited Works
- → Pembrolizumab for Early Triple-Negative Breast Cancer(2020)2,944 cited
- → Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer(2005)2,110 cited
- → Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer(2016)1,957 cited
- → Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer(2021)1,447 cited
- → RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer(2011)1,055 cited
- → Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer(2018)